BridgeBio Reports First Patient Dosing in P-I/II (ADventure) Trial for the Treatment of Congenital Adrenal Hyperplasia
Shots:
- The 1st patient has been dosed in P-I/II (ADventure) trial evaluating the safety, tolerability & PD of BBP-631 in patients with CAH
- The 1EPs of the study are safety, change from baseline in endogenous cortisol levels, steroid biomarkers for hydroxyprogesterone (17-OHP) levels & androstenedione (A4) levels. Preclinical PoC data showed the potential to provide efficient & persistent delivery of functional 21-hydroxylase (21-OH) enzyme to the adrenal gland
- BridgeBio’s portfolio also includes a clinical-stage program for Canavan disease & preclinical programs for classic galactosemia, TMC1 hearing loss & 3 others. The results are expected in H2’22 for CAH & Canavan disease
Ref: Globe Newswire | Image: Bridgebio
Click here to read the full press release
Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com
